BackRegulus Therapeutics Overview

Regulus Therapeutics Intangible Assets

Track Regulus Therapeutics's intangible assets ($23K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Intangible Assets
$23000.00
23.33% YoYΔ $-7000.00 vs prior year quarter

Peer average

Loading

Regulus Therapeutics Intangible Assets History

Loading

Regulus Therapeutics vs. peers: Intangible Assets Comparison

Loading

Regulus Therapeutics Intangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Regulus Therapeutics (RGLS) FAQ

Regulus Therapeutics (RGLS) currently reports a intangible assets of $23K as of March 2025. That compares with $30K in the prior-year period — down 23.3% year over year. Use the charts on this page to explore Regulus Therapeutics's intangible assets history and peer comparisons.

Regulus Therapeutics's intangible assets decreased from $30K to $23K — a 23.3% year-over-year decrease (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Regulus Therapeutics reported $23K in intangible assets as of March 2025. That compares with $30K in the prior-year period — down 23.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current intangible assets of $23K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Regulus Therapeutics, and consider following RGLS for alerts when major investors trade the stock.

Regulus Therapeutics is classified in the Healthcare sector. On intangible assets, it currently shows $23K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RGLS with unrelated industries.